Using blood tests to track cancer after pancreatic treatment
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer confirmed under the microscope as borderline resectable or locally advanced
- Your treatment plan includes “conversion therapy” (treatment aimed at shrinking the tumor so it may be operable)
- You’re 18 or older
- Your overall health is fairly good (ECOG score 0–2, meaning you can do most daily activities)
- You’re expected to live at least 3 months
- You have no other primary cancers at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This study uses a personalized blood test to look for tiny pieces of tumor DNA in people with pancreatic cancer. It helps doctors understand how the cancer changes during treatment.
This pilot study checks whether a special blood test (ctDNA) can detect cancer signals and work as well as another sample method during biopsies for liver, bile duct, or pancreatic cancers. It may help doctors choose the best way to confirm the diagnosis from biopsy samples.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.